Celiac Disease Market Growth Driven by Rising Diagnosis Rates and Global Adoption of Gluten-Free Diets

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Celiac Disease Market Size, Share & Trends Analysis Report By Treatments (Infliximab, Larazotide Acetate, Gluten Free Diet), Route Of Administration (Oral And Parenteral), End-Users (Hospitals, Homecare), And Distribution Channels (Hospital Pharmacy, Online Pharmacy, And Retail Pharmacy), Region, Market Outlook And Industry Analysis 2035"

Celiac Disease Market Size is valued at USD 0.68 Bn in 2025 and is predicted to reach USD 1.72 Bn by the year 2035 at a 9.8% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2874

Celiac disease is a long-term autoimmune condition precipitated by exposure to gluten, a protein found in wheat, barley, and rye. In affected individuals, gluten intake provokes an immune response that injures the mucosal lining of the small intestine, particularly the villi responsible for nutrient uptake. As a result, the absorption of essential nutrients-such as proteins, lipids, carbohydrates, vitamins, and minerals-is compromised, which may lead to nutritional deficiencies if the condition is not properly managed.

The global market for celiac disease solutions is expanding steadily, supported by rising disease incidence, improved public recognition, and continued progress in diagnostic capabilities. Key market developments include higher screening and diagnosis rates, a broader range of gluten-free food offerings, and increased research activity focused on disease-specific therapies. Growth is further reinforced by enhanced diagnostic precision, wider acceptance of gluten-free diets, and improved access to specialized products and services.

Nevertheless, the market is constrained by factors such as persistent underdiagnosis, uneven awareness levels, and stringent regulatory standards governing gluten-free labeling and compliance. Market segmentation by diagnostic approach, treatment modality, end-user group, and region enables stakeholders to design focused commercial strategies. Substantial opportunities exist for investment in novel diagnostics, next-generation therapeutics, and premium gluten-free solutions. With expanding global awareness and a stronger emphasis on effective disease management, the celiac disease market is positioned for continued long-term growth.

List of Prominent Players in the Celiac Disease Market:
• Amgen
• Anokion SA
• BioLineRx Ltd
• ChemoCentryx, Inc
• COUR Pharmaceutical
• F. Hoffmann-La Roche Ltd
• ImmunogenX, LLC
• Innovate Biopharmaceuticals
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
The global celiac disease market is demonstrating strong growth momentum, primarily due to the rising incidence of the condition, which is increasing demand for gluten-free food products and disease-specific therapeutic options. Greater public awareness of the adverse health effects associated with gluten consumption is further stimulating market development. In addition to medically diagnosed patients, a growing segment of consumers is voluntarily adopting gluten-free diets as awareness of gluten intolerance and sensitivity continues to expand.

Progress in diagnostic technologies has enabled earlier and more accurate identification of celiac disease, contributing to a larger treated patient population. At the same time, the expanding availability of gluten-free products across retail, hospitality, and foodservice channels has improved dietary compliance, reinforcing overall market growth.

Challenges:
Despite positive trends, several constraints continue to affect market performance. The premium pricing of gluten-free products limits affordability for certain consumer groups. Ongoing underdiagnosis-particularly in regions with low awareness-restricts effective disease management. In addition, compliance with strict labeling, certification, and food safety regulations creates operational complexity for manufacturers. In developing markets, weak distribution networks and limited product accessibility further impede market penetration.

Regional Trends:
North America holds a leading position in the global celiac disease market, supported by high diagnosis rates, strong healthcare expenditure, and the presence of established industry participants, with the United States serving as the primary revenue contributor. Meanwhile, the Asia-Pacific region is expected to register a high CAGR through 2032, driven by increasing awareness, expanding healthcare infrastructure, and large population bases. Within APAC, China accounts for the largest share, while India is emerging as the fastest-growing market due to improving diagnostic rates and rising health consciousness.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2874

Recent Developments:
• In June 2021, BioLineRx announced the start of a Phase 2b clinical trial for its flagship drug, BL-7010, as a therapy for celiac disease. The experiment will assess the safety and efficacy of BL-7010 in lowering gluten-induced symptoms and gut inflammation in celiac disease patients.
• In September 2022, ChemoCentryx recently announced encouraging results from a Phase 2 clinical trial of a new medication candidate for celiac disease-associated refractory sprue. The study found that refractory sprue, a severe form of celiac disease, showed encouraging results in terms of symptom reduction and intestinal health.

Segmentation of Celiac Disease Market-
By Treatments-
• Infliximab
• Larazotide Acetate
• Gluten-Free Diet
• Others
By Route of Administration-
• Oral
• Parenteral
By End-Users-
• Hospitals
• Homecare
• Others
By Distribution Channels-
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/celiac-disease-market/2874

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.